Evidence map›Paper›PMID 28722539›Full record

ArticleAutophagy2017

An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF

Shaun Martin, Aleksandra M Dudek-Peric, Abhishek D Garg, Heleen Roose, Seyma Demirsoy, Sofie Van Eygen, Freya Mertens, Peter Vangheluwe, Hugo Vankelecom, Patrizia Agostinis

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Autophagy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Purinergic CaCancers · 2024
    Article
  12. Review
  13. Purinergic CabioRxiv : the preprint server for biology · 2024
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shaun Martina Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine , University of Leuven (KU Leuven) , Campus Gasthuisberg , Leuven , Belgium.
Aleksandra M Dudek-Perica Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine , University of Leuven (KU Leuven) , Campus Gasthuisberg , Leuven , Belgium.
Abhishek D Garga Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine , University of Leuven (KU Leuven) , Campus Gasthuisberg , Leuven , Belgium.ORCID http://orcid.org/0000-0002-9976-9922
Heleen Roosec Department of Development and Regeneration, Cluster Stem Cell Biology and Embryology , University of Leuven (KU Leuven) , Campus Gasthuisberg, Leuven , Belgium.
Seyma Demirsoya Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine , University of Leuven (KU Leuven) , Campus Gasthuisberg , Leuven , Belgium.
Sofie Van Eygena Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine , University of Leuven (KU Leuven) , Campus Gasthuisberg , Leuven , Belgium.
Freya Mertensc Department of Development and Regeneration, Cluster Stem Cell Biology and Embryology , University of Leuven (KU Leuven) , Campus Gasthuisberg, Leuven , Belgium.
Peter Vangheluweb Laboratory of Cellular Transport Systems, Department of Cellular and Molecular Medicine , University of Leuven (KU Leuven) , Campus Gasthuisberg, Leuven , Belgium.
Hugo Vankelecomc Department of Development and Regeneration, Cluster Stem Cell Biology and Embryology , University of Leuven (KU Leuven) , Campus Gasthuisberg, Leuven , Belgium.
Patrizia Agostinisa Laboratory for Cell Death Research and Therapy, Department of Cellular and Molecular Medicine , University of Leuven (KU Leuven) , Campus Gasthuisberg , Leuven , Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ingrained capacity of melanoma cells to rapidly evolve toward an aggressive phenotype is manifested by their increased ability to develop drug-resistance, evident in the case of vemurafenib, a therapeutic-agent targeting BRAF

Indexed as

Adenosine TriphosphateAnimalsAutophagyCell Line, TumorCell MovementDrug Resistance, NeoplasmHumansIndolesMelanomaMiceMutationNeoplasm InvasivenessNeoplasm MetastasisPhenotypeProtein Kinase InhibitorsProto-Oncogene Proteins B-rafAdenosine TriphosphateIndolesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafReceptors, PurinergicSulfonamidesVemurafenibBRAFV600E inhibitor-resistanceextracellular ATPinvasionmacroautophagymelanomaP2RX7 receptorVemurafenib

Identifiers

PMID28722539
PMCPMC5612289
OpenAlexW2736538915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.